-
Innovation Ranking
NewInnovation Ranking – Intellia Therapeutics Inc
Intellia Therapeutics Inc (Intellia Therapeutics) is a biotechnology company. The company developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. It develops in vivo programs for the treatment of liver diseases such as alpha-1 antitrypsin deficiency, and primary hyperoxaluria Type 1. Intellia Therapeutics also develops ex vivo programs such as hematopoietic stem cells (HSCs) and chimeric antigen receptor T cells (CAR-T cells). The company’s pipeline products include OTQ923 / HIX763, NTLA-5001. The company conducts genome...
-
Company Insights
Innovation and Patenting activity of Intellia Therapeutics Inc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Intellia Therapeutics Inc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Hyperoxaluria – Drugs In Development, 2023
Global Markets Direct’s, ‘Hyperoxaluria - Drugs In Development, 2023’, provides an overview of the Hyperoxaluria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Primary Hyperoxaluria – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Hyperoxaluria - Drugs In Development, 2023’, provides an overview of the Primary Hyperoxaluria pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Primary Hyperoxaluria Type I – Drugs In Development, 2023
Global Markets Direct’s, ‘Primary Hyperoxaluria Type I - Drugs In Development, 2023’, provides an overview of the Primary Hyperoxaluria Type I pipeline landscape. The report provides comprehensive information on the therapeutics under development for Primary Hyperoxaluria Type I, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Alpha-1 Antitrypsin Deficiency (A1AD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Alpha-1 Antitrypsin Deficiency (A1AD) - Drugs In Development, 2023’, provides an overview of the Alpha-1 Antitrypsin Deficiency (A1AD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alpha-1 Antitrypsin Deficiency (A1AD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) - Drugs In Development, 2023’, provides an overview of the Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-INH] Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the...
-
Product Insights
Hemophilia B (Factor IX Deficiency) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemophilia B (Factor IX Deficiency) - Drugs In Development, 2023’, provides an overview of the Hemophilia B (Factor IX Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemophilia B (Factor IX Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Hemophilia A (Factor VIII Deficiency) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemophilia A (Factor VIII Deficiency) - Drugs In Development, 2023’, provides an overview of the Hemophilia A (Factor VIII Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemophilia A (Factor VIII Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...